The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Incyte; Miami Cancer Institute; Pfizer; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Sanofi; SERVIER
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Incyte; Isofol Medical; MSD; Pfizer; Roche
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
 
Stefan Kasper
Honoraria - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Lilly; Merck Serono; Roche; Sanofi
Other Relationship - Amgen; Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Sanofi
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss
 
Sebastian Stintzing
Honoraria - Amgen; Bayer; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; Sanofi; SERVIER; Takeda
Research Funding - Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Ralf Dieter Hofheinz
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Medac; Merck Serono; MSD; Roche; Sanofi; Servier
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Research Funding - German Cancer Aid (Inst); Medac (Inst); Sanofi (Inst)
 
Marianne Sinn
No Relationships to Disclose
 
Tobias Nicolaas Dechow
No Relationships to Disclose
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Incyte; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
 
Verena Keitel
No Relationships to Disclose
 
Ullrich Graeven
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; MSD Oncology; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Hexal; Johnson & Johnson; Merck KGaA; MSD Oncology
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Merck KGaA
 
Ludwig Fischer von Weikersthal
No Relationships to Disclose
 
Alexander Kolov
No Relationships to Disclose
 
Thomas Edelmann
No Relationships to Disclose
 
Alexander Stein
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Roche; SERVIER
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Tanja Trarbach
No Relationships to Disclose
 
Sabine Junge
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Isabel Virchow
No Relationships to Disclose
 
Jens T Siveke
Stock and Other Ownership Interests - FAPI Holding; Pharma15
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Baxalta; Bristol-Myers Squibb; Celgene; Immunocore; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Celgene; Roche
Travel, Accommodations, Expenses - AstraZeneca (Inst); Bristol-Myers Squibb; Celgene; Roche; SERVIER (Inst)
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Immutep; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; MorphoSys; Novartis; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)